Namandje Bumpus Sells 4,386 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Namandje Bumpus sold 4,386 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $3.54, for a total transaction of $15,526.44. Following the sale, the director directly owned 43,171 shares of the company’s stock, valued at approximately $152,825.34. This represents a 9.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $3.32 on Friday. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $2.77 and a fifty-two week high of $7.18. The firm has a 50-day simple moving average of $3.30 and a 200 day simple moving average of $3.82. The company has a market cap of $1.76 billion, a PE ratio of -2.77 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. The firm had revenue of $6.47 million during the quarter, compared to analyst estimates of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. Recursion Pharmaceuticals’s revenue was down 56.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.50) EPS. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current year.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in RXRX. International Assets Investment Management LLC acquired a new stake in Recursion Pharmaceuticals during the fourth quarter valued at approximately $31,000. Integral Investment Advisors Inc. acquired a new stake in Recursion Pharmaceuticals during the first quarter valued at approximately $39,000. Sequoia Financial Advisors LLC acquired a new stake in Recursion Pharmaceuticals during the fourth quarter valued at approximately $41,000. MQS Management LLC acquired a new stake in Recursion Pharmaceuticals during the first quarter valued at approximately $41,000. Finally, Allworth Financial LP lifted its stake in Recursion Pharmaceuticals by 85.6% during the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after purchasing an additional 4,403 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on RXRX shares. JPMorgan Chase & Co. cut their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Bank of America reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, February 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.10.

Key Headlines Impacting Recursion Pharmaceuticals

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Recursion’s recent business updates highlighted positive early clinical data and further progress in its AI drug-discovery pipeline, reinforcing investor optimism about the company’s long-term platform potential. Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results
• Positive Sentiment: The company reported a smaller-than-expected quarterly EPS loss and better-than-expected revenue in its latest earnings release, which helped support the recent rebound in the stock. Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
• Neutral Sentiment: Recent commentary also focused on Recursion’s valuation and the market’s patience with its AI-biotech story, suggesting investors are weighing pipeline upside against a still-uncertain commercialization timeline. Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation
• Negative Sentiment: CEO Najat Khan sold shares in a pre-arranged trading plan, and Director Namandje Bumpus also sold shares, adding a mild overhang as investors may view insider selling cautiously even though the transactions were planned in advance. SEC filing for CEO Najat Khan sale SEC filing for Director Namandje Bumpus sale

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.